Zobrazeno 1 - 10
of 145
pro vyhledávání: '"Gerald A, Soff"'
Publikováno v:
Cancer Medicine, Vol 13, Iss 15, Pp n/a-n/a (2024)
Abstract Chemotherapy‐induced thrombocytopenia (CIT) is a common challenge of cancer therapy and can lead to chemotherapy dose reduction, delay, and/or discontinuation, affecting relative dose intensity, and possibly adversely impacting cancer care
Externí odkaz:
https://doaj.org/article/b0417016656d4eadabb3ef2b20d98415
Autor:
Cy R. Wilkins, Jocelyn Ortiz, Leah J. Gilbert, Shen Yin, Jodi V. Mones, Rekha Parameswaran, Simon Mantha, Gerald A. Soff
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 6, Iss 3, Pp n/a-n/a (2022)
Abstract Background Chemotherapy‐induced thrombocytopenia (CIT) is common during treatment with antineoplastic therapies and may adversely impact chemotherapy dose intensity. There is no approved therapy for CIT. In our recent phase II randomized s
Externí odkaz:
https://doaj.org/article/55728aab962a421eb55e38afe5a64bc0
Autor:
Gerald A Soff, Isabelle Ray-Coquard, Luis J Marfil Rivera, Jon Fryzek, Megan Mullins, Lauren C Bylsma, Joseph K Park
Publikováno v:
PLoS ONE, Vol 17, Iss 6, p e0257673 (2022)
BackgroundCurrently, there are no approved options to prevent or treat chemotherapy-induced thrombocytopenia (CIT). We performed a systematic literature review and meta-analysis on use of thrombopoietic agents for CIT.Patients and methodsWe searched
Externí odkaz:
https://doaj.org/article/bd49d84b99e94a02bd85b6d4a280db95
Autor:
Jodi V. Mones, Michael B. Streiff, Alok A. Khorana, Gemma A. Bendheim, C. V. Damaraju, Peter Wildgoose, Paul Burton, Hanno Riess, Gerald A. Soff
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 5, Iss 5, Pp n/a-n/a (2021)
Abstract Background Prophylactic anticoagulation with rivaroxaban significantly reduced the risk of cancer‐associated thrombosis during the intervention period in the CASSINI trial. Direct oral anticoagulants may increase the risk of gastrointestin
Externí odkaz:
https://doaj.org/article/01708f1762434189891ef90745374b08
Autor:
Gerald A. Soff, Jodi Mones, Cy Wilkins, Sean Devlin, Eva Haegler‐Laube, Jonathan Wills, Debra M. Sarasohn, Krishna Juluru, Michael Singer, Yimei Miao, Jeanette Batista, Simon Mantha
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 3, Iss 3, Pp 349-356 (2019)
Abstract Background Low‐molecular‐weight heparin has been the preferred treatment of cancer‐associated thrombosis (CAT); however, emerging data support the use of direct oral anticoagulants (DOACs). Objectives The Memorial Sloan Kettering Cance
Externí odkaz:
https://doaj.org/article/de38ce3fe59344babff882290be6de04
Autor:
Michael Scordo, Leah J. Gilbert, Danielle M. Hanley, Jessica R. Flynn, Sean M. Devlin, Linh K. Nguyen, Josel D. Ruiz, Gunjan L. Shah, Craig S. Sauter, David J. Chung, Heather J. Landau, Oscar B. Lahoud, Richard J. Lin, Parastoo B. Dahi, Miguel-Angel Perales, Sergio A. Giralt, Gerald A. Soff
Publikováno v:
Blood Advances. 7:1536-1544
There are no standard treatments to prevent or hasten the recovery from severe conditioning-regimen–induced thrombocytopenia occurring after autologous hematopoietic cell transplantation (auto-HCT). We conducted an open-label, single-arm pilot stud
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e244dffe40a0b1da09124d3c7ed78c3
https://doi.org/10.1182/bloodadvances.2022007838
https://doi.org/10.1182/bloodadvances.2022007838
Autor:
Danny N. Khalil, Isabel Prieto González-Albo, Lee Rosen, Tom Lillie, Andrea Stacey, Lola Parfitt, Gerald A. Soff
Publikováno v:
Investigational New Drugs. 41:317-323
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d5fd536b190daefb3fbae6eecabf5bf1
https://doi.org/10.1007/s10637-023-01345-8
https://doi.org/10.1007/s10637-023-01345-8
Autor:
Alok A. Khorana, Mairéad G. McNamara, Ajay K. Kakkar, Michael B. Streiff, Hanno Riess, Ujjwala Vijapurkar, Simrati Kaul, Peter Wildgoose, Gerald A. Soff
Publikováno v:
TH Open, Vol 04, Iss 02, Pp e107-e112 (2020)
Introduction In the CASSINI study, rivaroxaban thromboprophylaxis significantly reduced primary venous thromboembolism (VTE) endpoints during the intervention period, but several thromboembolic events designated as secondary efficacy endpoints were n
Externí odkaz:
https://doaj.org/article/ee99dcca8b064679be805e3206169d47
Autor:
Tzu-Fei Wang, Alok A Khorana, Giancarlo Agnelli, Dan Bloomfield, Marc P Bonaca, Harry R Büller, Jean M Connors, Shinya Goto, Zhi-Cheng Jing, Ajay K Kakkar, Yasser Khder, Gary E Raskob, Gerald A Soff, Peter Verhamme, Jeffrey I Weitz, Marc Carrier
Publikováno v:
The Oncologist.
Cancer-associated thrombosis, with the incidence rising over the years, is associated with significant morbidity and mortality in patients with cancer. Recent advances in the treatment of cancer-associated venous thromboembolism (VTE) include the int
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e73e3468b7bf71019562badc2e14dd76
https://doi.org/10.1093/oncolo/oyad116
https://doi.org/10.1093/oncolo/oyad116
Autor:
Danny N. Khalil, Isabel Prieto González-Albo, Lee Rosen, Tom Lillie, Andrea Stacey, Lola Parfitt, Gerald A. Soff
Publikováno v:
Investigational New Drugs.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d99426b27bf5b7e1b2e58541c9cf091b
https://doi.org/10.1007/s10637-023-01369-0
https://doi.org/10.1007/s10637-023-01369-0